130 related articles for article (PubMed ID: 12879476)
21. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract][Full Text] [Related]
22. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.
Ifergan I; Meller I; Issakov J; Assaraf YG
Cancer; 2003 Nov; 98(9):1958-66. PubMed ID: 14584080
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
Nooij MA; Whelan J; Bramwell VH; Taminiau AT; Cannon S; Hogendoorn PC; Pringle J; Uscinska BM; Weeden S; Kirkpatrick A; Glabbeke Mv; Craft AW;
Eur J Cancer; 2005 Jan; 41(2):225-30. PubMed ID: 15661546
[TBL] [Abstract][Full Text] [Related]
24. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
25. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
[TBL] [Abstract][Full Text] [Related]
26. CD9 expression is not a prognostic factor in human osteosarcoma.
Kubista B; Erovic BM; Klinger H; Sulzbacher I; Trieb K
Cancer Lett; 2004 Jun; 209(1):105-10. PubMed ID: 15145525
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
29. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
30. Post operative infection and increased survival in osteosarcoma patients: are they associated?
Jeys LM; Grimer RJ; Carter SR; Tillman RM; Abudu A
Ann Surg Oncol; 2007 Oct; 14(10):2887-95. PubMed ID: 17653803
[TBL] [Abstract][Full Text] [Related]
31. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
32. Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
Wang W; Wang ZC; Shen H; Xie JJ; Lu H
Eur Rev Med Pharmacol Sci; 2014; 18(9):1383-90. PubMed ID: 24867518
[TBL] [Abstract][Full Text] [Related]
33. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
34. Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience.
Weiss A; Khoury JD; Hoffer FA; Wu J; Billups CA; Heck RK; Quintana J; Poe D; Rao BN; Daw NC
Cancer; 2007 Apr; 109(8):1627-37. PubMed ID: 17351949
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy.
Huang Y; Lin Z; Zhuang J; Chen Y; Lin J
Onkologie; 2008 Oct; 31(10):535-40. PubMed ID: 18854653
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic factors for 72 patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy].
Liu J; Guo W; Yang RL; Tang XD; Yang Y
Zhonghua Wai Ke Za Zhi; 2008 Aug; 46(15):1166-70. PubMed ID: 19094683
[TBL] [Abstract][Full Text] [Related]
37. Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor.
Sami SH; Rafati AH; Hodjat P
Saudi Med J; 2008 Aug; 29(8):1124-9. PubMed ID: 18690304
[TBL] [Abstract][Full Text] [Related]
38. [Neoadjuvant chemotherapy for osteosarcoma].
Guo W; Yang RL; Tang XD; Tang S; Li DS; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1186-90. PubMed ID: 15387981
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
Fan XL; Cai GP; Zhu LL; Ding GM
Drug Des Devel Ther; 2015; 9():5925-32. PubMed ID: 26604690
[TBL] [Abstract][Full Text] [Related]
40. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
